Higher blood levels of collagen-derived molecule predict worse outcomes
News | Heart Failure
Penn Study Identifies New Prognostic Biomarker for Heart Failure

September 29, 2022 — Bloodstream levels of a protein fragment called endotrophin can be used to predict outcomes in ...

Home September 29, 2022
Home
The multi-center first-in-men study evaluates the safety and performance of the next generation of BIOTRONIK’s Resorbable Magnesium Scaffold (RMS)
News | Stents Bioresorbable
BIOMAG-I Clinical Trial Reaches Primary Endpoint at Six Month for Unique Next Generation Resorbable Magnesium Scaffold

September 28, 2022 — In the "TCT Innovation" session Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator ...

Home September 28, 2022
Home
Yeonsik Now, UMass Amherst assistant professor who holds a joint appointment in the Elaine Marieb College of Nursing and the College of Engineering’s electrical and computer engineering department, was awarded a projected four-year, $2.3 million grant from the National Institutes of Health’s National Heart, Blood and Lung Institute. Image courtesy of UMass Amherst
News | Heart Failure
Wearing a Vest With Wireless Hardware for Five Minutes a Day May Help People With Heart Failure Stay Out of the Hospital

September 28, 2022 — A University of Massachusetts Amherst nurse engineer is leading a team of researchers who are ...

Home September 28, 2022
Home
Draper engineers are developing the Low-force Expanding/Adaptable Pediatric (LEAP) Valve—the first heart valve that can grow with the patient. Credit: Draper
News | Pediatric Cardiology
Draper Advances Growth-Adaptive Pediatric Heart Valve with Sutureless Adhesive

September 28, 2022 — Babies born with heart valve defects will have as many as 3 to 5 open heart surgeries before ...

Home September 28, 2022
Home
George Washington University Researchers have found that post-stroke language and orientation impairments predicted recurrent stroke, while attention deficit impairment was associated with increased risk of death.
News | Stroke
New Study Provides Insights into Stroke Recurrence and Death in Patients with Insulin Resistance

September 28, 2022 — George Washington University researchers have found that post-stroke language and orientation ...

Home September 28, 2022
Home
Heart disease prevention pioneer Jeremiah Stamler, MD. Photo courtesy of Legacy.com
Feature | Cardiovascular Business | By Christine Book
Spotlight on Heart Disease Prevention Pioneer, Jeremiah Stamler, MD

World Heart Day takes place each year on September 29. Founded in 2000 by the World Heart Federation, World Heart Day ...

Home September 28, 2022
Home
Martha Gulati, MD, is the new director of Preventive Cardiology in the Smidt Heart Institute. Photo by Cedars-Sinai.
News | Cardiovascular Business
Smidt Heart Institute Welcomes New Director of Preventive Cardiology

September 27, 2022 — Martha Gulati, MD, an expert in preventive cardiology and women’s heart disease, has joined the ...

Home September 27, 2022
Home
Magmaris Scaffold Performs Well in Real World Settings Even in More Complex Patient Groups
News | Stents Bioresorbable
BIOSOLVE-IV Full-Cohort Two-Year Data Confirm Excellent Safety and Efficacy Profile of Magmaris Resorbable Magnesium Scaffold

September 27, 2022 — BIOTRONIK announced the presentation of new full-cohort 2-year BIOSOLVE-IV data. In a poster ...

Home September 27, 2022
Home
a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock (SEISMiC) will be presented on October 2 at the Heart Failure Society of America Annual Scientific Meeting in Washington, DC.
News | Cardiogenic Shock
Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

September 27, 2022 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage ...

Home September 27, 2022
Home
Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards' breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve.
News | Heart Valve Technology
Edwards Launches Sapien 3 Ultra Resilia Valve Following FDA Approval

September 26, 2022 — Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates ...

Home September 26, 2022
Home
UC San Diego researchers have created the first diagnostic tool able differentiate between two similar pediatric inflammatory conditions, using a novel artificial intelligence-guided algorithm
News | Coronavirus (COVID-19)
How to Tell the Difference between Kawasaki Disease and MIS-C

September 26, 2022 — Kawasaki disease (KD) is the leading cause of acquired heart disease in children in developed ...

Home September 26, 2022
Home
Evolut FX TAVR System Adds Innovative Features to Enhance Ease-of-Use and Predictable Valve Deployment
News | Structural Heart
Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

September 26, 2022 — Medtronic plc, a global leader in medical technology, announced U.S. Food and Drug Administration ...

Home September 26, 2022
Home
Study of the Paradise Ultrasound Renal Denervation System Shows Significant Reduction in Blood Pressure in Patients with Uncontrolled Hypertension
News | Hypertension
ReCor Medical Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting

September 26, 2022 — ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the ...

Home September 26, 2022
Home
Avicenna.AI are a medical imaging AI developer, optimizing radiologists’ manual tasks and identifying acute abnormalities. This partnership involves their stroke product suite, which enables automatic identification and triage for acute stroke.
News | Artificial Intelligence
Avicenna.AI Partners With deepc to Revolutionize Stroke Patient Care

September 22, 2022 — Medical imaging specialist Avicenna.AI announced a groundbreaking partnership with the MedTech ...

Home September 22, 2022
Home
Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis.
News | Cardiogenic Shock
Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella ...

Home September 22, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now